• Explore /
  • Poster
  • / Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.

Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.

Abstract Poster

Authors

null

Luchia Andemicael

University of California, San Francisco, San Francisco, CA;

Luchia Andemicael , Hewitt Chang , Moshiur Mekhail Anwar , Kelly Bauer , John Gordan , Jamese Johnson , Bridget P Keenan , Alan P. Venook , Chia-Ching Jackie Wang , Karen Zhang , Lawrence Fong , Robin Kate Kelley , Mary Uan-Sian Feng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

04430452

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS630)

DOI

10.1200/JCO.2023.41.4_suppl.TPS630

Abstract #

TPS630

Poster Bd #

N19

Abstract Disclosures

Similar Posters

First Author: Sadahisa Ogasawara

First Author: Tae-Yong Kim

First Author: David Tougeron

First Author: Rafael Morales-Barrera